While at present there is a lack of extensive direct evidence that the alterations in pre-mRNA splicing caused by mutations in splicing factors are the main mechanism driving the disease in MDS, aberrant splicing of some key downstream target genes (e.g., ATP-binding cassette subfamily B member 7 [ABCB7] and enhancer of zeste 2 polycomb repressive complex 2 subunit [EZH2]) linked to splicing factor gene (SF3B1 and SRSF2) mutations has been shown to be associated with certain MDS disease aspects and phenotypes (12, 13). Here, SRSF2 is linked to myelodysplastic syndrome.